Spero Therapeutics, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    €23.60M -71.7% -€59.07M -400.6% -250.3% -2.7 pp -€20.20M -28.9% -85.6% -0.51 pp
    €83.34M +99.1% €19.65M -147.5% 23.6% +1.2 pp -€28.43M +326.8% -34.1% -0.18 pp
    €41.85M +166.1% -€41.38M -47.4% -98.9% +4.0 pp -€6.66M -88.0% -15.9% +3.4 pp
    €15.73M +95.7% -€78.66M +17.8% -500.1% +3.3 pp -€55.47M -24.9% -352.7% +5.7 pp
    €8.04M +96.8% -€66.79M +28.8% -830.9% +4.4 pp -€73.85M +72.4% -918.7% +1.3 pp
    €4.09M +19.6% -€51.84M +44.4% -1,269.0% -2.2 pp -€42.82M +33.7% -1,048.2% -1.1 pp
    €3.42M +100.4% -€35.89M -9.6% -1,050.5% +13 pp -€32.04M -4.8% -937.7% +10 pp
    €1.71M +490.7% -€39.71M +80.8% -2,329.3% +53 pp -€33.67M +38.9% -1,974.9% +64 pp
    €288.62K +∞% -€21.96M +151.0% -7,609.3% -76 pp -€24.23M +200.0% -8,396.7% -84 pp
    €0.00 -€8.75M N/A -€8.08M N/A

    Notifications